Skip to main contentSkip to navigation
Sirius Investors
Biogen Inc.

Biogen Inc.

BIIB
NASDAQHealthcare

Biogen Inc. (BIIB) Investment Research Dashboard

About Biogen Inc. (BIIB) stock analysis

Get live BIIB stock price $205.61, comprehensive Biogen Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time BIIB stock data and investment insights.

205.61
2.73%Today
Market Cap
30.36B
Volume
1.59M
52W High
219.72
52W Low
124.56

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addre...

Company Information

CEO
Christopher A. Viehbacher
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7500

Contact Information

Address
225 Binney Street
Country
US

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - General

Investment Highlights

Strong presence in the Healthcare sector with established market position

Valuation metrics suggest potential value opportunity (P/E: 13.0)

Lower volatility stock (Beta: 0.16) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Biogen Inc. shareholders
  • Market volatility can significantly impact stock price, especially for mid-cap stocks
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Biogen Inc.
  • Investors should consider how Biogen Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

30.36B

P/E Ratio (TTM)

12.98

Beta

0.16

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

78/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+3.1%+4.3%19.3
98/100⭐⭐⭐⭐⭐
Healthcare+0.7%+1.3%+1.6%24.1
78/100⭐⭐⭐⭐⭐
Communication Services+1.4%-0.7%+2.9%22.2
74/100⭐⭐⭐⭐⭐
Consumer Defensive-0.2%+1.8%+0.7%29.7
64/100⭐⭐⭐⭐
Basic Materials+0.4%+1.2%-0.2%25.2
61/100⭐⭐⭐⭐
Real Estate-0.5%+0.0%-2.5%29.2
43/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.1
39/100⭐⭐
Utilities-1.0%+0.0%-4.4%26.8
37/100⭐⭐
Industrials+0.6%+0.4%-9.9%30.1
23/100
Consumer Cyclical+0.5%-1.5%-5.8%43.0
18/100
Technology+0.6%-1.6%-7.2%40.7
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.